PARP1 and neoplasm: Radiotherapy, as well as its combination with surgery or chemotherapy, in this study, did not bring survival benefits to ovarian cancer patients, but some preclinical studies showed that PARP inhibitors might be sensitizing agents for radiotherapy; others also agreed that radiotherapy could promote tumor immunity cycle in OC, which implied the potential synergy of radiotherapy with targeted therapy or immunotherapy in OC [22–24].